Dr. Wagner on Responses Achieved With Nivolumab/Ipilimumab in Angiosarcoma


Michael Wagner, MD, discusses responses achieved with nivolumab plus ipilimumab in patients with angiosarcoma.

Michael Wagner, MD, an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Research Center, discusses responses achieved in the phase 2 DART trial with nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with angiosarcoma

Of the 4 patients who responded to the combination therapy, 2 have continued on treatment with durable responses of around 1 year, according to Wagner. Notably, several other patients experienced prolonged disease stability with this approach and continue on therapy despite that their tumors did not technically respond to treatment, notes Wagner.

This is not typically seen in patients with metastatic angiosarcomas, Wagner says. Most patients who had received treatment with the doublet therapy were pretreated with chemotherapy or other therapies, Wagner concludes.

Related Videos
Meredith McKean, MD, MPH
Damon R. Reed, MD
Brian A. Van Tine, MD, PhD
Breelyn A. Wilky, MD
Damon R. Reed, MD
R. Lor Randall, MD, FACS
Brian A. Van Tine, MD, PhD
Bernd Kasper, MD, PhD